Discover
TLSA
Tiziana Life Sciences Ltd
1.23
1 x 1.17
1 x 1.30
bid
ask
-
0.05
3.91%
1 @ 04:00 PM
1.24 +0.01 (0.85%)
| Ytd | -17.45% | |
| 1y | -20.65% |
1.17
day range
1.29
1.04
52 week range
2.60
| Open | 1.26 | Prev Close | 1.28 | Low | 1.17 | High | 1.29 | Mkt Cap | 156.53M |
| Vol | 144.47K | Avg Vol | 206.70K | EPS | -0.16 | P/E | N/A | Forward P/E | -13.63 |
| Beta | 0.18 | Short Ratio | 0.57 | Inst. Own | 1.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-08 | 50-d Avg | 1.31 | 200-d Avg | 1.53 | 1yr Est | 3.00 |
TLSA News
proactiveinvestors.com
Qualcomm raises long-term targets as analysts highlight data center, edge AI opportunities
Qualcomm Inc (NASDAQ:QCOM, XETRA:QCI) outlined higher long-term revenue and earnings targets at its
proactiveinvestors.com
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has rec
benzinga.com
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
globenewswire.com
Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial
Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, pl
benzinga.com
Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechno